Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00433043 · ClinicalTrials.gov registry record · Phase 4
BOAT: Beta Blocker Uptitration With OptiVol After Cardiac Resynchronization Therapy (CRT)
A Phase 4 study, sponsored by St. Luke's-Roosevelt Hospital Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT00433043 is a Phase 4 study that was terminated before completion, run by St. Luke's-Roosevelt Hospital Center. The registered enrollment target is 2 participants.
The verdict
NCT00433043, a Phase 4 study, was terminated before completion, sponsored by St. Luke's-Roosevelt Hospital Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
Many heart failure patients are unable to reach target beta blocker doses. This study will address whether cardiac resynchronization therapy (CRT) will enable uptitration of beta-blockers to target doses and whether it will favorably affect remodeling by reducing left ventricular end systolic volume (LVESV), with measurable clinical benefit, beyond CRT alone (without changes in beta-blocker dose).
Interventions
- DRUG Beta blocker (carvedilol or metoprolol succinate)
- PROCEDURE CRT (cardiac resynchronization therapy)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00433043
The ClinicalTrials.gov registry entry for NCT00433043 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Luke's-Roosevelt Hospital Center, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Beta blocker (carvedilol or metoprolol succinate) is the first listed.
NCT00433043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00433043 about?
NCT00433043 is a clinical study titled "BOAT: Beta Blocker Uptitration With OptiVol After Cardiac Resynchronization Therapy (CRT)". Many heart failure patients are unable to reach target beta blocker doses. This study will address whether cardiac resynchronization therapy (CRT) will enable uptitration of beta-blockers to target doses and whether it will favorably affect remodeling by reducing left ventricular end systolic volume...
What is the current status of trial NCT00433043?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2007-01. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00433043?
The interventions under investigation include: Beta blocker (carvedilol or metoprolol succinate) (DRUG), CRT (cardiac resynchronization therapy) (PROCEDURE).
Who is sponsoring clinical trial NCT00433043?
This trial is sponsored by St. Luke's-Roosevelt Hospital Center, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.